- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04079920
Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients (TREAT-RA)
BASELINE VARIABLES PREDICTING TREATMENT RESPONSE AT 6 MONTHS IN ADULT RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5MG BID IN A NON-INTERVENTIONAL SETTING (TREAT - RA)
This is a 24-month, prospective, non-interventional, multi-center study with primary aim to identify baseline characteristics of patients that predict response at 6 months of treatment. The study also aims to describe the treatment patterns of RA patients prescribed tofacitinib in a real-world setting and assess the effect of treatment on patient quality of life and physical function. Finally the study will assess the use of healthcare resources and costs in patients with RA treated with tofacitinib in Greece.
The planned recruitment period is 12 months. The planned observation period of each patient is 12 months. In this time period up to 4 visits will be documented.
The study will be reviewed and approved by the Central Regulatory Committee for NIS and IRB Board of each participating site
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Athens, Greece
- Laiko General Hospital of Athens
-
Athens, Greece, 11525
- 251 Air Force Hospital of Athens
-
Athens, Greece
- General Hospital of Athens Gennimatas
-
Athens, Greece
- Ippokrateio General Hospital of Athens
-
Athens, Greece
- Naval Hospital of Athens
-
Crete, Greece
- Nearchou 18
-
Heraklion, Greece
- Univerisity General Hospital of Heraklion
-
Ioannina, Greece, 45500
- University General Hospital of Ioannina
-
Kfisia, Greece
- KAT General Hospital of Attica
-
Larisa, Greece, 41110
- Univerisity General Hospital of Larisa
-
Larisa, Greece
- Univerisity General Hospital of Larisa
-
Patra, Greece
- Agios Andreas General Hospital of Patra
-
Patras, Greece, 26500
- University General Hospital of Patras
-
Thessaloniki, Greece
- EUROMEDICA General Clinic of Thessaloniki
-
Thessaloniki, Greece
- Euromedica Kyanous Stavros General Clinic
-
Thessaloniki, Greece
- General Hospital of Thessaloniki Ippokrateio
-
Voula, Greece
- Asklipieio General Hospital of Voula
-
-
Attiki
-
Athens, Attiki, Greece, 12462
- University General Hospital of Athens "ATTIKON"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Adult subjects with moderately to severely active rheumatoid arthritis who start treatment with tofacitinib in usual clinical practice conditions in compliance with the label
- Patients aged ≥ 18 years
- Confirmed Diagnosis of Rheumatoid Arthritis by rheumatologist
- Patients with moderate to severe RA diagnosed according to local practice who have already been started on treatment with tofacitinib, for at most seven working days .
- Patients eligible for tofacitinib treatment according to current approved Summary of Product Characteristics (SmPC).
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion Criteria:
Patients meeting any of the following criteria will not be included in the study:
- Exclusion Criteria according to the Xeljanz® SmPC.
- Contraindications to Xeljanz® according to SmPC.
- Hypersensitivity to the active substance (tofacitinib) or to any of the excipients.
- Active tuberculosis (TB), serious infections, such as sepsis, or opportunistic infections.
- Receipt of any investigational drug within 3 months before study inclusion as well as currently not participating in an interventional clinical trial.
- Subjects who have received any previous treatment with tofacitinib or other JAK inhibitors.
- Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Low Disease Activity (LDA)
Time Frame: month 6
|
Percentage of participants with Disease Score Activity (DAS28) less than 3.2.
|
month 6
|
Rate of remission
Time Frame: month 6
|
Percentage of participants with a Disease Activity Score (DAS28) less than 2.6
|
month 6
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A3921342
- TREAT-RA (Other Identifier: Alias Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia